PMID- 22821550
OWN - NLM
STAT- MEDLINE
DCOM- 20121220
LR  - 20120816
IS  - 1573-7233 (Electronic)
IS  - 0167-7659 (Linking)
VI  - 31 Suppl 1
DP  - 2012 Sep
TI  - Management of adverse events of targeted therapies in normal and special patients 
      with metastatic renal cell carcinoma.
PG  - S19-27
LID - 10.1007/s10555-012-9355-y [doi]
AB  - Treatment options for metastatic renal cell carcinoma (mRCC) have evolved very 
      rapidly, as reflected by the approval of the many drugs that have shown efficacy 
      in phase III studies. Approved drugs include tyrosine kinase inhibitors (TKI) 
      such as sunitinib, sorafenib and pazopanib, vascular endothelial growth factor 
      inhibitors such as bevacizumab, and mammalian target of rapamycin (mTOR) 
      inhibitors such as temsirolimus and everolimus. These biological agents have 
      toxicity profiles that differ from those accompanying current chemotherapeutic 
      agents, but their novelty leads to a lack of exhaustive clinical data regarding 
      related adverse events (AEs), whose symptoms may overlap with those of the 
      chronic illnesses of patients with mRCC such as hypertension, hyperglycemia, and 
      pneumonitis. Hypertension, hypothyroidism, hand-foot syndrome, and fatigue are 
      AEs frequently associated with TKIs; whereas immunosuppression, stomatitis, 
      metabolic alterations, and non-infectious pneumonitis are AEs of mTOR inhibitors. 
      Recommendations for treating these adverse events in patients with mRCC are 
      usually the same as those for the general population. Mild to moderate toxicities 
      may be managed with supportive and pharmacologic interventions, but higher-grade 
      toxicities usually require external specialist consultation, dose reductions, and 
      treatment interruption or discontinuation. Some groups of patients with mRCC, 
      such as frail, elderly patients, and patients with renal or liver dysfunction, 
      require special management of AEs.
FAU - Mendez-Vidal, Maria Jose
AU  - Mendez-Vidal MJ
AD  - Hospital Provincial de Cordoba, Cordoba, Spain. mariajose.mendezvidal@gmail.com
FAU - Martinez Ortega, Esther
AU  - Martinez Ortega E
FAU - Montesa Pino, Alvaro
AU  - Montesa Pino A
FAU - Perez Valderrama, Begona
AU  - Perez Valderrama B
FAU - Viciana, Ruth
AU  - Viciana R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Cancer Metastasis Rev
JT  - Cancer metastasis reviews
JID - 8605731
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/pathology/secondary
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Neoplasm Metastasis
EDAT- 2012/07/24 06:00
MHDA- 2012/12/21 06:00
CRDT- 2012/07/24 06:00
PHST- 2012/07/24 06:00 [entrez]
PHST- 2012/07/24 06:00 [pubmed]
PHST- 2012/12/21 06:00 [medline]
AID - 10.1007/s10555-012-9355-y [doi]
PST - ppublish
SO  - Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S19-27. doi: 
      10.1007/s10555-012-9355-y.